Mestinon

Pyridostigmine, the active ingredient in Mestinon, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It is employed to improve muscle strength in patients with myasthenia gravis and to reverse the effects of non‑depolarizing neuromuscular blocking agents after surgery, especially in chronic management of the disease.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global logistics for this essential medication.

Mestinon (pyridostigmine) acts on the cholinergic neuromuscular junction to improve transmission in specific disorders.

- Myasthenia gravis: improves skeletal muscle strength and reduces fatigue. - Reversal of neuromuscular blockade (off‑label): accelerates recovery from non‑depolarizing muscle relaxants after surgery. - Congenital myasthenic syndromes: enhances neuromuscular transmission in inherited disorders.

Pyridostigmine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: increased bowel movements. - Abdominal cramps: intermittent stomach pain. - Excessive salivation: watery mouth. - Muscle cramps: involuntary tightening of muscles. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Cholinergic crisis: severe muscle weakness and respiratory failure. - Bronchospasm: narrowing of airways causing breathing difficulty. - Bradycardia: abnormally slow heart rate. - Cardiac arrhythmias: irregular heart rhythms. - Seizures: rare convulsive episodes. - Severe hypotension: sudden drop in blood pressure.

When prescribing pyridostigmine, several safety considerations should be observed.

- Renal impairment: adjust dose in patients with reduced kidney function. - Cardiac conditions: monitor for bradycardia or arrhythmias. - Respiratory disease: use cautiously in asthma or COPD. - Gastrointestinal obstruction: avoid in patients with mechanical obstruction. - Concomitant anticholinergics: review for possible antagonism. - Store at ambient temperature: keep in original packaging, protect from moisture.

Pyridostigmine can affect, or be affected by, other medicines.

Major Interactions (Avoid): - Other cholinesterase inhibitors: additive cholinergic effects may precipitate crisis. - Succinylcholine: potentiates neuromuscular blockade, increasing risk of prolonged paralysis. - Beta‑blockers: may exacerbate bradycardia.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs (e.g., atropine): reduce therapeutic efficacy. - Cardiac glycosides (e.g., digoxin): may increase risk of arrhythmias. - Certain antibiotics (e.g., fluoroquinolones): can enhance neuromuscular transmission effects.